AztraZeneca's Tagrisso Plus Chemotherapy Extended Median Progression-free Survival By Nearly 9 Months In EGFR-Mutated Advanced Lung Cancer In FLAURA2 Phase 3 Trial
Portfolio Pulse from Benzinga Newsdesk
AztraZeneca's Tagrisso plus chemotherapy has extended median progression-free survival by nearly 9 months in EGFR-mutated advanced lung cancer in the FLAURA2 Phase 3 trial. The trial included patients with locally advanced or metastatic non-small cell lung cancer.
September 11, 2023 | 8:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AztraZeneca's successful trial of Tagrisso plus chemotherapy could potentially boost its stock in the short term.
The successful trial results of Tagrisso, a product of AztraZeneca, could potentially increase the demand for the company's stock. This is because successful trial results often lead to increased sales of the product, which can boost the company's revenues and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
AztraZeneca's successful trial of Tagrisso plus chemotherapy could potentially boost its stock in the short term.
The successful trial results of Tagrisso, a product of AztraZeneca, could potentially increase the demand for the company's stock. This is because successful trial results often lead to increased sales of the product, which can boost the company's revenues and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100